Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with rising global prevalence, requiring effective management to prevent complications. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including luseogliflozin, are a novel class of drugs that provide benefits beyond glycemic control. This umbrella review synthesized evidence from multiple systematic reviews and meta-analyses to evaluate the efficacy and safety of luseogliflozin in T2DM patients. Following Joanna Briggs Institute (JBI) guidelines and PRISMA standards, eligible studies included systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies involving adult T2DM patients treated with luseogliflozin. A comprehensive literature search was performed in PubMed, EMBASE, and Web of Science up to June 10, 2024. Data extraction and quality assessment were independently conducted by two reviewers, and statistical analyses were performed using R software version 4.3. Fourteen systematic reviews were included, showing that luseogliflozin significantly reduced HbA1c levels (pooled mean difference -1.784, 95% CI: -3.99 to -0.431), fasting plasma glucose (FPG) levels (-3.165, 95% CI: -4.046 to -2.284), and postprandial glucose (PPG) levels (-37.148, 95% CI: -65.361 to -8.935) compared with placebo. Additional benefits included significant reductions in body weight (-1.322 kg, 95% CI: -1.58 to -1.056), triglycerides (-13.891, 95% CI: -26.539 to -1.243), uric acid (-0.350, 95% CI: -0.524 to -0.176), and alanine aminotransferase (ALT) levels (-7.345, 95% CI: -5.845 to -1.463). No significant increase in hypoglycemia risk was observed (pooled risk ratio 1.305, 95% CI: 0.692 to 2.459). These findings suggest that luseogliflozin is an effective and safe treatment for T2DM, offering substantial benefits in glycemic control, weight management, blood pressure lowering, and metabolic parameters, with a favorable safety profile regarding hypoglycemia. Further long-term studies are warranted to establish its definitive role in clinical practice and support broader regulatory approvals.
No takes yet. Share an insight, caveat, or question.
Shabil et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: